Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion.
White M, Haddad H, Leblanc MH, Giannetti N, Pflugfelder P, Davies R, Isaac D, Burton J, Chan M, Azevedo E, Howlett J, Ignaszewski A, Busque S, Cantarovich M, Ferguson R, Genest J, Ross H. White M, et al. Among authors: leblanc mh. J Heart Lung Transplant. 2005 Jul;24(7):798-809. doi: 10.1016/j.healun.2004.05.023. J Heart Lung Transplant. 2005. PMID: 15982605 Clinical Trial.
Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
White M, Lepage S, Lavoie J, De Denus S, Leblanc MH, Gossard D, Whittom L, Racine N, Ducharme A, Dabouz F, Rouleau JL, Touyz R. White M, et al. Among authors: leblanc mh. J Card Fail. 2007 Mar;13(2):86-94. doi: 10.1016/j.cardfail.2006.10.013. J Card Fail. 2007. PMID: 17395047 Clinical Trial.
A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure.
de Denus S, Dubé MP, Fouodjio R, Huynh T, LeBlanc MH, Lepage S, Sheppard R, Giannetti N, Lavoie J, Mansour A, Provost S, Normand V, Mongrain I, Langlois M, O'Meara E, Ducharme A, Racine N, Guertin MC, Turgeon J, Phillips MS, Rouleau JL, Tardif JC, White M; CANDIID II investigators. de Denus S, et al. Among authors: leblanc mh. Pharmacogenomics. 2018 May;19(7):599-612. doi: 10.2217/pgs-2018-0004. Epub 2018 Apr 27. Pharmacogenomics. 2018. PMID: 29701105 Clinical Trial.
The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: focus on rehabilitation and exercise and surgical coronary revascularization.
Canadian Cardiovascular Society Heart Failure Management Primary Panel; Moe GW, Ezekowitz JA, O'Meara E, Howlett JG, Fremes SE, Al-Hesayen A, Heckman GA, Ducharme A, Estrella-Holder E, Grzeslo A, Harkness K, Lepage S, McDonald M, McKelvie RS, Nigam A, Rajda M, Rao V, Swiggum E, Virani S, Van Le V, Zieroth S; Canadian Cardiovascular Society Heart Failure Management Secondary Panel; Arnold JM, Ashton T, D'Astous M, Dorian P, Giannetti N, Haddad H, Isaac DL, Kouz S, Leblanc MH, Liu P, Ross HJ, Sussex B, White M. Canadian Cardiovascular Society Heart Failure Management Primary Panel, et al. Among authors: leblanc mh. Can J Cardiol. 2014 Mar;30(3):249-63. doi: 10.1016/j.cjca.2013.10.010. Epub 2013 Oct 19. Can J Cardiol. 2014. PMID: 24480445 Review.
123 results